AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Rhea-AI Summary
Amgen (NASDAQ:AMGN) will present at the 2026 J.P. Morgan Healthcare Conference at 3:45 p.m. PT on Monday, January 12, 2026. Robert A. Bradway, chairman and chief executive officer, will deliver the presentation. The event will be webcast live and available to media, investors and the public via Amgen's website under Investors. Presentation times and webcast links are listed on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – AMGN
On the day this news was published, AMGN declined 3.37%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AMGN gained 2.95% while close peers were mixed: GILD +2.66%, BMY +2.29%, PFE +0.97%, SNY +0.08%, and GSK -0.26%. No broad sector momentum flag was triggered.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 19 | Pricing & investment update | Positive | +0.9% | Outlined lower U.S. drug prices and >$2.5B incremental U.S. manufacturing spend. |
| Dec 11 | FDA approval | Positive | +0.1% | FDA approved UPLIZNA for adults with generalized myasthenia gravis subtypes. |
| Dec 09 | Dividend declaration | Positive | +0.5% | Announced Q1 2026 dividend of $2.52 per share with set record and pay dates. |
| Nov 24 | Investor conference | Neutral | +2.0% | Planned presentation at Citi’s 2025 Global Healthcare Conference with webcast replay. |
| Nov 24 | Investor conference | Neutral | +2.0% | Announced Evercore ISI HealthCONx presentation with webcast and 90-day replay. |
Recent company news, including conference appearances, dividends and regulatory milestones, has typically seen modestly positive next-day price reactions.
Over the past few months, Amgen has combined strategic pricing actions, regulatory wins and regular investor outreach. On Dec 19, 2025, it outlined U.S. pricing moves and significant U.S. manufacturing investments. An FDA approval for UPLIZNA in generalized myasthenia gravis arrived on Dec 11, 2025. The Board declared a $2.52 per-share Q1 2026 dividend on Dec 9, 2025. Multiple December conferences, including Citi and Evercore ISI events, were also webcast. Today’s J.P. Morgan appearance continues this pattern of active investor communication.
Market Pulse Summary
This announcement highlights Amgen’s participation in the 44th J.P. Morgan Healthcare Conference on January 12, 2026, with a webcast at 3:45 p.m. PT and replay available for at least 90 days. It continues a pattern of active investor engagement alongside recent milestones such as the UPLIZNA FDA approval and a $2.52 Q1 2026 dividend. Investors may focus on management’s strategic commentary and how it builds on prior pricing, investment, and regulatory updates.
AI-generated analysis. Not financial advice.
The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.
In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.
For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn, Instagram, YouTube and Threads.
CONTACT: Amgen,
Elissa Snook, 609-251-1407 (media)
Casey Capparelli, 805-447-1746 (investors)
View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302655380.html
SOURCE Amgen